Nicotine from cigarette smoking is a potent CYP1A2 inhibitor, and its abrupt discontinuation during hospitalization removes this inhibitory effect, allowing CYP1A2 activity to return to its uninduced baseline

This restoration of normal enzyme function paradoxically reduces clozapine clearance because the CYP1A2 system was previously operating in an inhibited-but-compensated state. The rebound phenomenon in CYP1A2 activity overshoots baseline function, creating a transient period of subnormal enzyme activity. This rebound hypofunction is analogous to receptor upregulation after chronic antagonist exposure and results in transient clozapine accumulation. This answer incorrectly identifies nicotine as the active component and describes the mechanism in the wrong direction. Nicotine itself does not significantly induce or inhibit CYP1A2. The polycyclic aromatic hydrocarbons (PAHs) in cigarette smoke, not nicotine, are potent CYP1A2 inducers.

Polycyclic aromatic hydrocarbons in cigarette smoke are potent inducers of CYP1A2, the primary enzyme responsible for clozapine metabolism

Chronic smoking substantially increases CYP1A2 enzyme expression and activity, and clozapine doses in smokers are titrated to account for this enhanced clearance. When smoking abruptly ceases, CYP1A2 enzyme levels gradually decline toward their uninduced baseline over approximately one to two weeks, progressively reducing clozapine clearance. The unchanged clozapine dose combined with declining metabolic capacity produces a steady accumulation of the drug, ultimately reaching toxic concentrations that manifest as the observed seizure, sedation, and autonomic dysfunction. Cigarette smoke contains polycyclic aromatic hydrocarbons that are potent CYP1A2 inducers through activation of the aryl hydrocarbon receptor. This induction can increase CYP1A2 activity by 1.5- to 3-fold.

Cigarette smoking increases hepatic blood flow through nicotine-mediated sympathetic activation, which enhances the delivery of clozapine to hepatic metabolizing enzymes and increases its clearance through a flow-dependent extraction mechanism

When smoking cessation eliminates the chronic sympathetic stimulation, hepatic blood flow decreases by approximately 30-40%, reducing the rate at which clozapine is delivered to and extracted by the liver. This hemodynamic mechanism is independent of any changes in enzyme expression or activity and is rapidly reversible with nicotine replacement therapy. The effect is most pronounced for high-extraction-ratio drugs like clozapine that have flow-dependent hepatic clearance. Clozapine is not a high-extraction-ratio drug, and its hepatic clearance is primarily capacity-limited (enzyme-dependent) rather than flow-dependent.

The acute inflammatory response from pneumonia produces elevated levels of interleukin-6 and other proinflammatory cytokines that directly and rapidly inhibit all cytochrome P450 enzyme families, including CYP1A2, CYP2D6, CYP3A4

CYP2C19, through transcriptional downregulation. This inflammation-mediated pan-CYP inhibition reduces the metabolism of all hepatically cleared medications and is the primary mechanism responsible for drug accumulation during acute illness. Smoking cessation is an incidental finding in this case and does not contribute significantly to the pharmacokinetic change. The clozapine levels would have risen similarly in a nonsmoker hospitalized with pneumonia. While inflammation-mediated CYP inhibition through proinflammatory cytokines is a real pharmacologic phenomenon and can contribute to altered drug metabolism during acute illness, it is not the primary mechanism in this scenario.